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Semicritical medical devices are defined as items that come into contact with mucous membranes or 
nonintact skin (eg, gastrointestinal endoscopes, endocavitary probes). Such medical devices minimally 
require high-level disinfection. Because many of these items are temperature sensitive, low-temperature 
chemical methods are usually used rather than steam sterilization. Strict adherence to current guide-
lines is required because more outbreaks have been linked to inadequately cleaned or disinfected endoscopes 
and other semicritical items undergoing high-level disinfection than any other reusable medical device.
In theUnitedStates in2010, therewere approximately 51.4million
inpatient surgical procedures and an even larger number of invasive
medical procedures.1 For example, therewere >6.9millionupper gas-
trointestinal (GI), 11.5million lowerGI, and228,000biliaryendoscopies
performed in 2009.2 Each of these procedures involves contact by a
medical device or surgical instrument with a patient’s sterile tissue
ormucousmembranes. Amajor risk of all such procedures is the in-
troductionof pathogenicmicrobes,which can lead to infection. Failure
to properly disinfect or sterilize equipment may lead to transmis-
sion via contaminatedmedical and surgical devices (eg, carbapenem-
resistant Enterobacteriaceae [CRE]).3,4
Multiple studies in many countries have documented the lack
of compliance with established guidelines for disinfection and
sterilization.5 Failure to complywith scientifically based guidelines
has led to numerous outbreaks and patient exposures. In fact, nearly
all infections and patient exposures associated with reprocessing
medical or surgical instruments involve high-level disinfection (HLD)
of reusable semicritical items6-8 Because of noncompliancewith rec-
ommended reprocessing procedures, the Centers for Disease Control
and Prevention (CDC) and the Food and Drug Administration (FDA)
issued a health advisory alerting health care providers and facili-
ties about thepublic healthneed toproperlymaintain, clean, disinfect,
and sterilize reusable medical devices in September 2015.9 In this
expanded and updated version of a previous article on this subject,10
wewill examine new technologies and issues for HLD of semicritical
items. Because semicritical items carry the greatest risk of infec-
tion we also will discuss reprocessing semicritical items, such as
endoscopes (and automated endoscope reprocessors [AERs]),
nasopharyngoscopes, endocavitary probes, prostate biopsy probes,
tonometers, laryngoscopes, transesophageal echocardiogramprobes,
infrared coagulation devices, and urologic instruments.
A RATIONAL APPROACH TO DISINFECTION AND STERILIZATION
Almost 50 years ago, Spaulding11 devised a rational approach to
disinfection and sterilization of patient care items or equipment.
This classification scheme is so clear and logical that it has been re-
tained, refined, and successfully used by infection control
professionals and others when planning methods for disinfection
or sterilization.12-15 Spaulding believed that the nature of disinfec-
tion could be understood more readily if instruments and items for
patient care were divided into 3 categories based on the degree of
risk of infection involved in the use of the items. The 3 categories
he described were critical (enters sterile tissue and must be sterile),
semicritical (contact with mucous membranes and requires HLD),
and noncritical (comes in contact with intact skin and requires low-
level disinfection). Although the scheme remains valid, there are
some examples of disinfection studies with viruses, mycobacteria,
and protozoa that challenge the current definitions and expecta-
tions of high- and low-level disinfection.16
Semicritical items
Semicritical items are those that come in contact with mucous
membranes or nonintact skin. Respiratory therapy and anesthesia
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equipment, GI endoscopes, bronchoscopes, laryngoscopes,
transesophageal echocardiogram (TEE) probes, tonometers,
endocavitary probes, prostate biopsy probes,17 cystoscopes,
hysteroscopes, infrared coagulation devices, and diaphragm fitting
rings are included in this category. These medical devices should
be free of all microorganisms (ie, mycobacteria, fungi, viruses, bac-
teria); however, small numbers of bacterial spores may be present.
Intact mucous membranes, such as those of the lungs or the GI tract,
generally are resistant to infection by common bacterial spores but
susceptible to other organisms, such as bacteria, mycobacteria, and
viruses. Semicritical items minimally require HLD using chemical
disinfectants. Glutaraldehyde, hydrogen peroxide, ortho-
phthalaldehyde, peracetic acid, and peracetic acid with hydrogen
peroxide, and a chlorine-based system are cleared by the FDA18 and
are dependable high-level disinfectants provided the factors influ-
encing germicidal procedures are met. The exposure time for most
high-level disinfectants varies from 8-45 minutes at 20°C-25°C.18
When a disinfectant is selected for use with certain patient care
items, the chemical compatibility after extended use with the items
to be disinfected also must be considered.
Because semicritical equipment has been associated with re-
processing errors that result in patient lookback and patient
notifications, it is essential that control measures be instituted to
prevent patient exposure.7 Before new equipment (especially
semicritical equipment as the margin of safety is less than that for
sterilization)19 is used for patient care on >1 patient, reprocessing
procedures for that equipment should be developed. Staff should
receive training on the safe use and reprocessing of the equip-
ment and be competency tested. At the University of North Carolina
Hospitals, to ensure patient-safe instruments, all staff that repro-
cess semicritical instruments (eg, instruments which contact a
mucous membrane, such as vaginal probes, endoscopes, and pros-
tate probes) are required to attend a 3-hour class on HLD of
semicritical instruments. The class includes the rationale for and
importance of HLD, discussion of HLD and exposure times, repro-
cessing steps, monitoringminimum effective concentration, personal
protective equipment, and reprocessing environment (establish dirty-
to-clean flow). Infection control rounds or audits should be conducted
annually in all clinical areas that reprocess critical and semicritical
devices to ensure adherence to the reprocessing guidelines, manu-
facturers’ instructions for use, and institutional policies. This includes
reprocessing critical and semicritical medical and surgical instru-
ments in outpatient care facilities because many patient exposures
and infections have occurred in this setting.20,21 Results of infec-
tion control rounds should be provided to the unit managers, and
deficiencies in reprocessing should be corrected and the correc-
tive measures documented to infection control within 30 days.
However, patient safety issues (such as wrong contact time, tem-
perature, or concentration of high-level disinfectant) require
immediate correction.
Semicritical items that will have contact with mucous mem-
branes should be rinsed with sterile water or filtered water or tap
water followed by an alcohol rinse.15,22 An alcohol rinse and forced
air drying markedly reduces the likelihood of contamination of the
instrument (eg, endoscope), most likely by removing the wet en-
vironment favorable for bacterial growth.23 After rinsing, items should
be dried and stored in a manner that protects them from damage
or contamination. Drying also retards biofilm formation.24
Semicritical items represent the greatest risk of disease trans-
mission because far more health care–associated infections have
been caused by reusable semicritical items than critical or non-
critical items.25 There is virtually no documented risk of transmitting
infectious agents to patients via noncritical items26 when they are
used as noncritical items and do not contact nonintact skin or
mucous membranes. Similarly, critical items are rarely,27 if ever,
associated with disease transmission. In contrast, semicritical items
(eg, GI endoscopes), by virtue of the body cavities they enter, may
contain 107-10 (7-10 log10) enteric microorganisms.28,29 Therefore,
any deviation from proper reprocessing (eg, crevices associated with
the elevator channel of a duodenoscope) could lead to failure to
eliminate contamination with a possibility of subsequent patient-
to-patient transmission. This low (or nonexistent) margin of safety
associated with endoscope reprocessing compares with the 17 log10
margin of safety associated with cleaning and sterilization of sur-
gical instruments.19,25 This is the reason that semicritical items
represent the greatest risk of disease transmission via a reusable




Physicians use endoscopes to diagnose and treat numerous
medical disorders. Although endoscopes represent a valuable di-
agnostic and therapeutic tool inmodernmedicine, more health care–
associated outbreaks and patient exposures have been linked to
contaminated endoscopes than to any other reusable medical
device.6,8 Additionally, endemic transmission of infections associ-
ated with GI endoscopes may go unrecognized for several reasons,
including inadequate surveillance of outpatient procedures, long lag
time between colonization and infection, low frequency of infec-
tion, and the pathogens transferred by the endoscope are the usual
enteric flora. In addition, the infection risk of some procedures might
be lower than others (eg, colonoscopy vs endoscopic retrograde
cholangiopancreatography [ERCP]) where normally sterile areas are
contaminated in the latter. To prevent the spread of health car–
associated infections, all heat-sensitive endoscopes (eg, GI
endoscopes, bronchoscopes, nasopharyngoscopes) must be prop-
erly cleaned and, at a minimum, subjected to HLD after each use.
HLD can be expected to destroy all microorganisms; however, when
high numbers of bacterial spores are present, a few spores may
survive.
Recommendations for the cleaning and disinfection of endo-
scopic equipment have been published and should be strictly
followed.15,22,30 Unfortunately, largely because of instrument com-
plexity, audits have shown that personnel do not adhere to guidelines
on reprocessing5 and outbreaks of infection continue to occur.3,4,6,8,31
Additionally, recent studies have suggested that current reprocess-
ing guidelines are not sufficient to ensure successful
decontamination,32 and some AERs have been recalled because of
violations that include the inability of the unit to validate that the
AER can adequately wash and disinfect endoscopes to mitigate the
risk of patient infection.33 To minimize patient risks and ensure
that reprocessing personnel are properly trained, there should be
initial and annual competency testing for each individual who is
involved in reprocessing endoscopic instruments.15,22,30
In general, HLD of an endoscope involves the following 5 steps
after leak testing: (1) clean—mechanically clean internal and ex-
ternal surfaces, including brushing internal channels and flushing
each internal channel with water and an enzymatic cleaner or de-
tergent; (2) disinfect—immerse endoscope in a high-level disinfectant
(or chemical sterilant) and perfuse (eliminates air pockets and
ensures contact of the germicide with the internal channels) dis-
infectant into all accessible channels, such as the suction or biopsy
channel and air or water channel and expose for a time recom-
mended for the specific products; (3) rinse—rinse the endoscope
and all channels with sterile water, filtered water (commonly used
with AERs), or tap water; (4) dry—rinse the insertion tube and inner
channels with alcohol and dry with forced air after disinfection and
before storage; and (5) store—store the endoscope in a way that pre-
vents recontamination and promotes drying (eg, hung vertically).15,22
Outbreaks of CRE infection associated with duodenoscopes: What
can we do to prevent infections?
In the last 3 years, multiple reports of outbreaks have led the
FDA, CDC, and national news to raise awareness among the public
and health care professionals that the complex design of
duodenoscopes (used primarily for ERCP) may impede effective re-
processing. Several recent publications have associatedmultidrug-
resistant bacterial infections, especially CRE in patients who have
undergone ERCP,with reprocessed duodenoscopes.3,4,19,31,34,35 Unlike
other endoscope outbreaks,6 these recent outbreaks occurred even
when the manufacturer’s instructions and professional guidelines
were followed correctly.3,4
The key concern raised by these outbreaks is that current re-
processing guidelines are not adequate to ensure a patient-safe GI
endoscope (one devoid of potential pathogens) because the margin
of safety associatedwith reprocessing endoscopes is minimal or non-
existent. There are at least 2 (and maybe 3) reasons for this
reprocessing failure and why outbreaks continue to occur.19 First,
studies have shown that the internal channel of GI endoscopes, in-
cluding duodenoscopes, may contain 107-10 (7-10 log10) enteric
microorganisms.28,29 Investigations have demonstrated that the clean-
ing step in endoscope reprocessing results in a 2-6 log10 reduction
of microbes and the HLD step results in another 4-6 log10 reduc-
tion of mycobacteria for a total 6-12 log10 reduction of microbes.28,29,36
Therefore, the margin of safety associated with cleaning and HLD
of GI endoscopes is minimal or nonexistent (level of contamina-
tion: 4 log10 [maximum contamination, minimal cleaning/HLD] to
−5 log10 [minimum contamination, maximum cleaning/HLD]). There-
fore, any deviation from proper reprocessing (eg, crevices associated
with the elevator channel) could lead to failure to eliminate con-
tamination with a possibility of subsequent patient-to-patient
transmission. This low (or nonexistent) margin of safety associ-
atedwith endoscope reprocessing compares with the 17 log10 margin
of safety associated with cleaning and sterilization of surgical
instruments.19
Second, GI endoscopes not only have heavy microbial contam-
ination (107-1010 bacteria) but they are complex, with long, narrow
channels; right angle turns; and difficult to clean and disinfect com-
ponents (eg, elevator channel). The elevator channel in
duodenoscopes is unique to side-viewing endoscopes. It has a sep-
arate channel and provides orientation of catheters, guide wires, and
accessories into the endoscopic visual field.19 This channel is complex
in design and has crevices that are difficult to access with a clean-
ing brush and may impede effective reprocessing.37 Based on this
and other recent studies, it is likely that multidrug-resistant patho-
gens are acting as a marker or indicator organism for ineffective
reprocessing of the complex design of duodenoscopes, which is an
infectious risk to patients.
Third, biofilms could impact endoscope reprocessing failure and
continued endoscope-related outbreaks.38 Biofilms are multilay-
ered bacteria plus exopolysaccharides that cement cells to surfaces.
They develop in a wet environment. If reprocessing is performed
promptly after use and the endoscope is dry, the opportunity for
biofilm formation is minimal.39,40 However, the formation of endo-
scopic biofilm during clinical practice may be related to reuse of
reprocessing methods, such as reuse of detergent, manual clean-
ing, and incomplete drying.41 Ideally, reprocessing should be initiated
with an hour of use; however, there are no evidence-based guide-
lines on delayed endoscope reprocessing.42 It is unclear if biofilms
contribute to failure of endoscope reprocessing.
What should we do now? Unfortunately, there is currently no
single, simple, and proven technology or prevention strategy that
hospitals can use to guarantee patient safety. Of course, we must
continue to emphasize the enforcement of evidence-based prac-
tices, including equipment maintenance and routine audits in areas
that reprocess semicritical items (eg, GI, urology), with at least
yearly competency testing of reprocessing staff.15,22,30 All reprocess-
ing personnel must be knowledgeable and thoroughly trained on
the reprocessing instructions for duodenoscopes. This includes
the new recommendations to use a small bristle cleaning brush
and for additional flushing and cleaning steps of the elevator
channel.43 Although these steps were described as validated, no
public data are available on the ability of these new cleaning
recommendations to yield an ERCP scope devoid of bacteria.
However, we must do more or additional outbreaks will likely
continue. For example, all hospitals that reprocess duodenoscopes
should select one of the enhanced methods for reprocessing
duodenoscopes. These enhancedmethods have been priority ranked
with the first providing the greatest margin of safety.19 They include
the following: (1) ethylene oxide sterilization after HLD with pe-
riodic microbiologic surveillance; (2) double HLD with periodic
microbiologic surveillance; (3) HLD with scope quarantine until
negative culture results are returned; (4) liquid chemical sterilant
processing system using peracetic acid (rinsed with extensively
treated potable water) with periodic microbiologic surveillance;
(5) other FDA-cleared low-temperature sterilization technology
(provided material compatibility and sterilization validation testing
performed using the sterilizer and endoscope) after HLD, with
periodic microbiologic surveillance; and (6) HLD with periodic
microbiologic surveillance. These supplemental measures to enhance
duodenoscope reprocessing made in May-June 201519 were rein-
forced by the FDA in August 2015.37 University of North Carolina
Hospitals have chosen ethylene oxide sterilization after HLD with
periodic microbiologic surveillance as its primary reprocessing
method for duodenoscopes, and if the ethylene oxide sterilizer is
not available, then double HLD with periodic microbiologic sur-
veillance is performed.44
Infection preventionists should ensure that institutional poli-
cies are consistent with national guidelines and manufacturers’
instructions for use and conduct infection control rounds period-
ically (eg, at least annually) in areas where endoscopes and other
semicritical items are reprocessed to make certain there is com-
pliance with policy. Breaches in policy should be documented and
corrective action instituted. In incidents in which endoscopes and
other semicritical items were not exposed to a HLD process, pa-
tients were assessed for possible acquisition of HIV, hepatitis B virus,
and hepatitis C virus. A 14-step method for managing a failure in-
cident associated with HLD or sterilization has been described.7 The
possible transmission of bloodborne pathogens and other infec-
tious agents highlights the importance of rigorous infection
control.21,45,46
Nasopharyngoscopes
Flexible nasopharyngoscopes are a valuable tool enabling easy
visualization of the upper aerodigestive tract. The following 3 tech-
niques are available to reprocess nasopharyngoscopes: manual HLD,
use of an AER, and use of a disposable sheath.15,47,48 However, because
sheaths, condoms, or covers may have tears or breaks that com-
promise their integrity, there was hesitation to allow the use of a
sheath to alter the recommendation of HLD. Now, there are 2 peer-
reviewed publications that validate the integrity of the sheath with
nasopharyngoscopes.
One study showed that the use of a high-quality, snugly fitting,
sterile, disposable polyurethane sheath on nasopharyngoscopes
during a clinical examination, combined with enzymatic deter-
gent cleaning and disinfection with 70% ethanol, provided a reliably
decontaminated, patient-ready instrument which eliminated the
need for HLD of nasopharyngoscopes.49 Another study found that
the contamination rate on nasopharygolaryngoscopes (FNPLs) with
the sheath alonewas similar to the contamination rate with the high-
level disinfected scope. The authors concluded that using the
individually packaged disposable sterile sheath of a FNPL pre-
vented microbes from adhering to the shaft of the scope, therefore
providing a safe method of avoiding the transmission of infection
from one patient to the next patient when using a FNPL succes-
sively in multiple patients in an otolaryngology clinic.50 Because we
now have 2 studies that corroborate the integrity of the sterile poly-
urethane sheaths used with nasopharyngoscopes, this practice (use
of a high-quality, snugly fitting, sterile, disposable sheath on a na-
sopharyngoscope during a clinical examination, combined with
enzymatic detergent cleaning and disinfection with 70% ethanol)
can provide a reliably decontaminated, patient-ready instrument
and may be an option for HLD. Therefore, we believe that with this
specific sheath and this device (ie, nasopharyngoscope), this prac-
tice of using this sheath plus cleaning plus alcohol may be an option
for HLD.
Tonometers
Disinfection strategies for other semicritical items (eg, appla-
nation tonometers, rectal or vaginal probes) are highly variable.
Currently, the FDA requests that the device manufacturer include
at least 1 validated cleaning and disinfection-sterilization proto-
col in the labeling for their device. As with all medications and
devices, users should be familiar with the label instructions. In view
of the potential for transmission of viruses (eg, herpes simplex virus,
adenovirus type 8, HIV)51 by tonometer tips, the CDC recommended52
that the tonometer tips be wiped clean and disinfected for 5-10
minutes with either 3% hydrogen peroxide, 5,000 ppm chlorine, 70%
ethyl alcohol, or 70% isopropyl alcohol. However, data demon-
strate that 3% hydrogen peroxide and 70% isopropyl alcohol are not
effective against adenovirus capable of causing epidemic kerato-
conjunctivitis and similar viruses and should not be used for
disinfecting applanation tonometers.53-55 For this reason, the CDC
guideline now recommends to wipe clean tonometer tips and then
disinfect them by immersing for 5-10 minutes in either 5,000 ppm
chlorine or 70% ethyl alcohol.15,52-55 Structural damage to Schiotz to-
nometers has been observed with a 1:10 sodium hypochlorite
(5,000 ppm chlorine) and 3% hydrogen peroxide.56 After disinfec-
tion, the tonometer should be thoroughly rinsed in tap water and
air dried before use. We believe that wiping the tonometer tips with
only a 70% isopropyl alcohol wipe is insufficient because 2 reports
have found that disinfection of pneumotonometer tips between uses
with a 70% isopropyl alcohol wipe contributed to outbreaks of ep-
idemic keratoconjunctivitis caused by adenovirus type 8.57,58
Endocavitary probes
Vaginal probes are used in sonographic scanning. A vaginal probe
and all endocavitary probes without a probe cover are semicritical
devices because they have direct contact with mucous mem-
branes (eg, vagina, rectum, pharynx). Although one could argue that
the use of the probe cover changes the category, the CDC guide-
line for disinfection and sterilization proposes that a new condom
or probe cover should be used to cover the probe for each patient,
and because condoms and probe covers may fail,59-63 HLD of the
probe also should be performed.15 The relevance of this recom-
mendation is reinforced with the findings that sterile transvaginal
ultrasound probe covers have a very high rate of perforations even
before use (0%, 25%, and 65% perforations from 3 suppliers).62 After
oocyte retrieval use, Hignett and Claman found a very high rate of
perforations in used endovaginal probe covers from 2 suppliers (75%
and 81%),62 whereas Amis et al64 and Milki and Fisch59 demon-
strated a lower rate of perforations after use of condoms (0.9% and
2.0%, respectively). Rooks et al found that condoms were superior
to commercially available probe covers for covering the ultra-
sound probe (1.7% leakage for condoms vs 8.3% leakage for probe
covers).65 These studies underscore the need for HLD of endocavitary
probes between examinations. Although most ultrasound manu-
facturers recommend the use of 2% glutaraldehyde for HLD of
contaminated transvaginal transducers, the use of this agent has been
questioned66 because it may shorten the life of the transducer and
may have toxic effects on the gametes and embryos.67 An alterna-
tive procedure for disinfecting the vaginal transducer has been
offered by Garland and de Crespigny.68 It involves the mechanical
removal of the gel from the transducer, cleaning the transducer in
soap and water, wiping the transducer with 70% alcohol or soaking
it for 2 minutes in 500 ppm chlorine, and rinsing with tap water
and air drying. The effectiveness of this method has not been vali-
dated in rigorous laboratory experiments. Another probe disinfection
method that uses a ultraviolet C chamber has been evaluated and
is used in Europe, but it is not yet FDA-cleared for use in the United
States.63,69
HLD with a FDA-cleared high-level disinfectant (eg, acceler-
ated hydrogen peroxide) that is not toxic to staff, patients, probes,
and retrieved cells should be used until such time as the effective-
ness of alternative procedures against microbes of importance at
the cavitary site is demonstrated by well-designed experimental sci-
entific studies. Other probes such as rectal, cryosurgical, and
transesophageal probes and devices should also be subjected to HLD
between patients.
Ultrasound probes may also be used during surgical proce-
dures and have contact with sterile body sites. These probes may
be covered with a sterile sheath to reduce the level of contamina-
tion on the probe and reduce the risk of infection. However, because
the sheath does not provide complete protection of the probe, the
probes should be sterilized between each patient use as with other
critical items. If this is not possible, minimally high-level disinfect
the probe and cover it with a sterile probe cover.
Some cryosurgical probes (eg, used in prostate cancer) are not
fully immersible. When reprocessing these probes, the tip of the
probe should be immersed in a high-level disinfectant for the ap-
propriate time (eg, 20 minutes of exposure with 2% glutaraldehyde),
and any other portion of the probe that could have mucous mem-
brane contact should be disinfected by immersion or wrapping with
a cloth soaked in a high-level disinfectant to allow for the recom-
mended contact time. After disinfection, the probe should be rinsed
with tap water and dried before use. Health care facilities that use
nonimmersible probes should replace them as soon as possible with
fully immersible probes.
As with other HLD procedures, proper cleaning of probes is nec-
essary to ensure the success of the subsequent disinfection.70
Muradali et al demonstrated a reduction of vegetative bacteria in-
oculated on vaginal ultrasound probeswhen the probeswere cleaned
with a towel.71 No information is available on either the level of con-
tamination of such probes by potential viral pathogens, such as
hepatitis B virus and human papilloma virus,72 or their removal by
cleaning (eg, with a towel). Because these pathogens may be present
in vaginal and rectal secretions and contaminate probes during use,
HLD of the probes after such use is recommended.
The CDC guideline for disinfection and sterilization states that
even if probe covers have been used, clean and high-level disin-
fect the semicritical devices, such as rectal probes, vaginal probes,
and cryosurgical probes, with a product that is not toxic to staff,
patients, probes, and retrieved germ cells (if applicable). Use a high-
level disinfectant at the FDA-cleared exposure time unless scientific
studies and guidelines recommend an alternative time and tem-
perature (eg, glutaraldehyde at 20 minutes, 20°C).15,22 When probe
covers are available, use a probe cover or condom to reduce the
level of microbial contamination. Do not use a lower category of
disinfection or cease to follow the appropriate disinfectant recom-
mendations when using probe covers because these sheaths and
condoms may fail (see the exception for nasopharyngoscopes and
1 tested sheath previously mentioned). After HLD, rinse all items.
Use sterile water, filtered water, or tap water followed by an alcohol
rinse for semicritical equipment that will have contact with the
mucousmembranes of the upper respiratory tract (eg, nose, pharynx,
esophagus).15
Hydrogen peroxide mist system for probes
An alternative procedure for disinfecting the endocavitary and
surface probes is a hydrogen peroxide mist system, which uses 35%
hydrogen peroxide at 56°C with the probe reaching no more than
40°C (ie, Trophon EPR; Nanosonics, Fishers, Fall Creek, IN). In one
study, the results demonstrated complete inactivation (>6 log10 re-
duction) of vancomycin-resistant Enterococcus and a CRE–Klebsiella
pneumoniae strain both in the presence and absence of 5% fetal calf
serum (FCS). The Trophon EPR system showed good, but not com-
plete, inactivation of Mycobacterium terrae (5.2 log10 reduction for
M terraewith FCS and 4.6 log10 reduction forM terraewithout FCS)
and Clostridium difficile spores (5.1 log10 reduction for C difficile spores
with FCS and 6.2 log10 reduction for C difficile spores without FCS).73
To simulate a worst-case condition, cleaning was not done prior to
disinfection in these experiments, but proper cleaning of probes is
necessary to ensure the success of HLD. Other data have demon-
strated the activity of the Trophon system to inactivate human
papilloma virus74 and other pathogens (eg, bacteria, mycobacte-
ria, viruses), including a >6 log10 reduction ofM terrae and C difficile
spores in carrier tests and a >6 log10 reduction in M terrae on in-
oculated ultrasound probes.75 These results differ slightly from those
previously mentioned, presumably because of the differences in
testing methodology. In our study only the probe devices were in-
oculated (carriers of different materials were not tested), and for
recovery of bacteria on the probe, the probes were immersed in
media (not swabbed, which would likely result in lower recovery).73
The Trophon system processes the portion of the probe that has
mucous membrane contact but also the handle of the endocavitary
probe, which may be contaminated, and it is an alternative to high-
level chemical disinfection for ultrasound probes.
Prostate biopsy probes
Transrectal ultrasound–guided prostate biopsies are among the
most common outpatient diagnostic procedures performed in
urology practice to evaluate patients for prostate cancer after an el-
evated prostate-specific antigen level or abnormal digital rectal
examination findings.76 It involves obtainingmultiple prostate tissue
cores by passing a disposable biopsy needle through a needle guide
under ultrasound guidance. All prostatic biopsy procedures result
in contamination of the probe with blood or feces. During this pro-
cedure, the transducer assembly is generally covered with a barrier
sheath.77 Breaches in the reprocessing of prostate biopsy probes can
pose a risk of disease transmission.76,78
Disinfection or sterilization of ultrasound transducer compo-
nents is based on the function or use of each component. Because
the biopsy needle penetrates sterile tissue for biopsy, it should be
sterile. Ideally, the needle guide should be sterilized between patient
use. However, if this is not possible (ie, clinic does not have a ster-
ilizer because biopsy needles are likely purchased as single-use sterile
devices), then HLD after disassembly and cleaning is acceptable
because it has contact withmucousmembranes but not sterile tissue.
The FDA alert77 and a CDC article76 recommend that the needle guide
be sterilized because the biopsy needle contacts the needle guide
before it penetrates sterile tissue. This recommendation is incon-
sistent with current recommendation for the disinfection of GI
endoscopes. It is currently recommended that GI endoscopes be high-
level disinfected minimally but that medical devices that pass
through the endoscope and enter sterile tissue (eg, biopsy forceps)
be sterilized.15,22 There is no recommendation that the lumen or
channel through which they pass should also be sterilized. One pos-
sible explanation for the inconsistency in this FDA recommendation
is that the GI endoscopes can only be high-level disinfected because
there is no practical way to sterilize them, whereas the reusable
needle guide for prostate probes can be sterilized (M.J. Arduino,
August 2006, written communication). Although a barrier sheath
is used on the transducer assembly during the biopsy procedure,
the sheath is compromised by the penetration of the needle.77 Al-
though prostate probes and other endocavitary probes are often
covered with a disposable sheath or condom,77 such covers do not
adequately protect the probe frommicrobial contamination caused
by leakage (9%)79; therefore, the use of a cover does not alter the
requirement for minimal HLD.15 The FDA specifies the use of a sterile
barrier sheath in their recommendation for reprocessing reusable
ultrasound transducer assemblies.77 It is appropriate to use a sterile
barrier sheath when an ultrasound probe is entering a sterile body
cavity, but when the probe is entering the rectum, the need for a
sterile barrier sheath is unclear.
All semicritical and critical medical devices must be thor-
oughly cleaned with enzymatic or nonenzymatic detergents before
they are subjected to a HLD or sterilization process, respectively.
Brushes should be used, when possible, to effectively clean the trans-
ducer assemblies, especially the lumens. Our investigation shows
that the needle guide and prostate probe can be effectively disin-
fected with glutaraldehyde, but the needle guide must be
disassembled from the transducer assembly before HLD.17
The FDA issued a Public Health Notification in June 2006 as a
result of follow-up to the Department of Veterans Affairs, Veter-
ans Health Administration Patient Safety Alert related to a particular
company’s ultrasound transducer assemblies. During patient safety
rounds, the lumen of a needle guide of an ultrasound transducer
assembly was found to be soiled. The FDA guidance consisted of
several steps80 for the complete method recommend by the FDA).
We have evaluated the FDA steps and suggest some modifications
(Table 1). Do not reuse items labeled for single use (eg, single-use
biopsy needles, needle guides). Additional recommendations may
be available in the operator’s manuals or user guides. It is impor-
tant that these recommendations be consistent with disinfection
and sterilization guidelines and principles or that these recom-
mendations have been validated by appropriate scientific studies.
Do not use any disinfectant that can cause irreparable damage to
the materials used to construct the probe. For example, if an alcohol
rinse is not compatible with the probe, rinse with sterile water (not
filtered water or tap water) and do not rinse with alcohol. These
recommendations could be adapted to all ultrasonic prostate probes
to include those with an external needle guide attachment.
Transesophageal echocardiogram probes (TEE)
The TEE probe is another semicritical device that has a poten-
tial for infection between sequential patients. Two bacterial outbreaks
(Escherichia coli and Pseudomonas aeruginosa) have been associ-
ated with damaged TEE probes used in cardiovascular surgical
operations.81,82 Once the damaged TEE probes were removed from
use, no additional cases were identified in the cardiac surgery pa-
tients. The defect presumably prevented exposure of the bacteria
to the high-level disinfectant. To ensure proper HLD, health care fa-
cilities should ensure the probe is not damaged and comply with
recommendations from professional organizations and the manu-
facturer. The basic principles for successful reprocessing of the probe
involve the following: clean the probe shaft and probe tip (via im-
mersion or wiped with a wipe moistened with detergent or
enzymatic cleaner) to remove gross contamination (a second wipe
is used to wipe nonimmersible parts higher up, including the
handle); inspected to ensure no structural damage; disinfect with
a high-level disinfectant (distal tip and flexible shaft are im-
mersed in the high-level disinfectant; wipe the higher portions with
a compatible disinfectant); thoroughly rinse; and dry before storage.83
Protective sheaths are an additional physical barrier to infection and
probe damage; however, they do not remove the possibility of in-
fection because sheaths do not cover all of the TTE probes and the
sheaths are subject to perforations.84 Strict adherence to manufac-
turers’ instructions when using chemical disinfectants such as ortho-
phthalaldehyde for TEE probe reprocessing is required to avoid
aerodigestive tract chemical injury.85 TEE probes require HLD re-
gardless of whether a sheath is used. Many hospitals use a vapor
control system that reduces exposure of staff to toxic vapors and
damage to the instrument (eg, wall rack holder such as a glutaral-
dehyde user station). Follow the manufacturer’s instructions or
professional organizational guidelines for soak times, cleaners, and
so forth.
Infrared coagulation
Infrared coagulation is a widely used method for treating hem-
orrhoids. The procedure involves applying infrared light to compress
and seal hemorrhoid veins. The manufacturer of the device sells a
sterile disposable sheath and states removing and soaking light
guides between procedures is no longer required. The manufactur-
er also states that the light guide is damaged by immersion in a
disinfectant because the light guide is not sealed at the end and the
disinfectant gets between the quartz glass and the covering.
As mentioned, the CDC guideline recommends immersion for re-
processing endocavitary probes with covers because integrity of the
cover is compromised. Because the light guide cannot be im-
mersed, we investigated an alternative procedure. This procedure
involved wiping the probe for 2 minutes with a 1:10 bleach
(5,000 ppm), and after that is completed, the probe is wiped with
sterile water and air dried. This procedure has been found effec-
tive in eliminating approximately 7 log10 reduction (7.8 × 106) ofM
terrae and is used at our hospital for decontamination of the sheathed
device after use.86
Laryngoscopes
Laryngoscopes are routinely used to view the vocal cords and
larynx and facilitate airway management. It typically consists of a
blade that connects to a handle which usually contains 2 batteries
that power the light source. Limited guidelines are available for re-
processing laryngoscope blades and handles, and hospital practices
vary.87-89 For example, some guidelines recommend and hospitals
use low-level disinfection of the handle because it does not have
direct contact with a mucous membrane, whereas others recom-
mend the handle be high-level disinfected to prevent disease
transmission. Although blades have been linked to health care–
associated infections, handles have not been directly linked to health
care–associated infections. However, reports of contamination with
blood (40% of the handles were positive for occult blood) and po-
tentially pathogenic microorganisms (86% of the handles deemed
“ready for patient use” were positive for Staphylococcus aureus,
Acinetobacter spp, etc) suggest the handles infection risk,89-92 and
the blade and handle function together. For this reason, it is ideal
that the blades and handles be high-level disinfected or sterilized
even if a protective barrier or sheath is used during the proce-
dure. In 2007, the State of California required that both blades and
handles be HLD or sterilized. UNC Hospitals are sterilizing the blades
and handles (ie, blades sterilized via hydrogen peroxide gas plasma,
handle [without batteries] sterilized by steam). Other methods for
HLD or sterilization are acceptable, but ensure the blade and handle
are compatible with the HLD or sterilization process chosen. After
sterilization, the blades and handles are checked for function prior
to packaging and then packaged in a sealed plastic bag. Per The Joint
Commission, the laryngoscope blade and handle must be pack-
aged in a way that prevents recontamination after processing
(Frequently Asked Questions from The Joint Commission October
24, 2011). Examples of compliant storage include, but are not limited
to, a peel pack poststerilization (long-term storage) or wrapping in
a sterile towel (short-term storage).
Recent advances in video technology have led to the develop-
ment of video laryngoscopes, such as the GlideScope (Verathon,
Seattle, WA) and McGRATH MAC (Covidien; Medtronic, Minneap-
olis, MN) video laryngoscopes. These new intubation devices assist
in difficult airway management. For the McGRATH MAC, an image
is displayed on a liquid-crystal display screen that is containedwithin
a monitor mounted to the handle of the device. A sterile, single-
use disposable laryngoscope blade covers the camera and light-
emitting diode assembly to prevent direct patient contact. Even
though a cover is used, HLD or sterilization via ethylene oxide or
hydrogen peroxide gas plasma (battery removed) is recommended
for the McGRATH MAC video laryngoscope.93 The manufacturer
states, whenever practical, HLD or sterilization is preferred to a wipe-
based process.
The portable GlideScope video laryngoscope system is avail-
able in a single-use and a reusable configuration. It should be cleaned
and disinfected per themanufacturer’s recommendations. The single-
use system features a reusable video baton and sterile Stats thatmust
be disposed of immediately after use. Low-level disinfection
Table 1
Recommendation for reprocessing the transrectal ultrasound prostate biopsy probes*
Cleaning
• Clean immediately after use
• Disassemble the transducer (remove needle guide from the probe)
• Brush clean (if possible) or flush each lumen and thoroughly clean all
surfaces of reusable components with enzymatic or nonenzymatic
detergent
• Rinse with tap water
• Dry with disposable cloth or towel or air dry
• Visibly inspect the entire device to ensure it is clean
High-level disinfection or sterilization
• Steam sterilize all heat-stable reusable components
• Alternatively, high-level disinfect the probe and needle guide separately
after disassembly
• High-level disinfect all heat-sensitive components (ensure disinfectants
reach all areas inside the lumens, and the minimum effective
concentration of the high-level disinfectant is monitored)
• Rinse with sterile water, filtered water, or tap water (FDA specifies sterile
water for rinsing)
• If filtered water or tap water is used, follow with an alcohol rinse (not
immersion of the probe in alcohol) to enhance drying (and no residual
water is left for microbial growth)
• Dry the device
• Appropriately store the device to ensure the device is not recontaminated
FDA, Food and Drug Administration.
*Users should be familiar with the manufacturer’s recommendations for use and dis-
infection of the specific device used by the facility.
Adapted with permission from Cambridge University Press.17
is recommended for the video baton after each use using an Envi-
ronmental Protection Agency–registered disinfectant (eg,
antimicrobial disposable wipe per the manufacturer’s instruc-
tions). HLD is recommended by themanufacturer for the video baton
when it is visibly soiled.
The manufacturer recommends that the advanced video laryn-
goscope reusable blade be high-level disinfected and the GlideRite
rigid stylets be sterilized.94
Other channeled endoscopes (cystoscopes, ureteroscopes, and
hysteroscopes)
In the United States, it is estimated that >4 million cystosco-
pies are performed each year. Cystoscopy is a diagnostic procedure
that uses an endoscope especially designed to examine the bladder,
lower urinary tract, and prostate gland or is used to collect urine
samples, perform biopsies, and remove small stones. A flexible or
rigid scope can be used to carry out the procedure. Because the pro-
cedure involves a medical device in contact with the patient’s
mucous membranes, it is considered a semicritical device that must
minimally be high-level disinfected. Failure to properly high-level
disinfect or sterilize equipment can lead to transmission of
infection.95,96
A recent study demonstrated how important it is to perfuse the
high-level disinfectant into the channel of cystoscopes and other
channeled scopes (eg, hysteroscopes, ureteroscopes). This study dem-
onstrated that disinfection (ie, a reduction in bacterial load of >7
log10 colony forming units) did not occur unless the channel was
actively perfused with glutaraldehyde. In fact, failure to perfuse the
channel led to only minimal, if any, reduction in bacterial contam-
ination. However, complete inactivation of 108 colony forming units
of both vancomycin-resistant Enterococcus and CRE was achieved
when the channel was actively perfused. It appears that no high-
level disinfectant entered the channel unless it was actively perfused
because the level of microbial contamination was not reduced by
immersion. This occurs because the air pressure in the channel is
stronger than the fluid pressure at the fluid-air interface. Recom-
mendations are provided for cystoscope HLD and include actively
perfusing the device while immersed in the high-level disinfectant.96
Cystoscopes have also been implicated as the source of infec-
tion in multiple patients when incorrect disinfection methods were
identified.95 This may, in part, be related to the lack of awareness
of recommendations specifically for disinfecting cystoscopes97 or
failing to follow the manufacturer’s instructions, which specify per-
fusing the lumen using a high-level disinfectant. Unfortunately, some
cystoscope reprocessing recommendations published in the liter-
ature are incorrect. For example, authors have recommended
complete immersion of the cystoscope into the high-level disin-
fectant, but they did not mention perfusion of the high-level
disinfectant into the channel.95 We suggest following our recom-
mendations (Table 2) and those of the American Urological
Association97 until evidence-based guidelines have been pub-
lished. Anaphylactic reactions have been reported in patients with
bladder cancer who underwent repeated cystoscopy using scopes
that were HLD with ortho-phthalaldehyde; therefore, ortho-
phthalaldehyde is contraindicated in patients with a history of
bladder cancer.97
Other issues affecting semicritical items
Storage of semicritical items
In 2011, The Joint Commission recommended that laryngo-
scope blades be packaged in a way that prevents recontamination.
Examples of compliant storage include, but not limited to, a peel
Table 2
Recommendations for reprocessing a flexible cystoscope*
• Preclean: immediately (within 1 h) after use to reduce microbes and organic matter. Gross debris should be wiped off the outside of the scope using a soft,
disposable cloth or sponge and water with an enzymatic or nonenzymatic detergent. Channels should be flushed with the same solution.
• Pressure/leak testing: should be performed to ensure that the flexible covering and the channels are intact. It should be done after each use and before
reprocessing, according to manufacturer’s guidelines.
• Clean: carefully clean channels with suitable cleaning brushes (see manufacturer’s recommendations) and flush or rinse to remove any loosened organic matter;
thoroughly clean all external surfaces using a soft, disposable cloth or brush with enzymatic or nonenzymatic detergent. Again, water with an enzymatic or
nonenzymatic detergent should be used for cleaning and flushing the channels. Detachable parts of the cystoscope, such as valves, adapters, and caps, should be
removed according to the manufacturer’s recommendations prior to cleaning and high-level disinfection.
• Rinse with tap water
• Dry with soft, lint-free cloth or towel (preferably disposable) or air dry
• Visibly inspect the entire device to ensure it is clean
• Reusable brushes should be high-level disinfected after each use
• Because enzymatic and nonenzymatic detergents are not microbicidal, they should be discarded after each use
• High-level disinfection
• High-level disinfect the cystoscope by completely immersing in the high-level disinfectant and perfusing the high-level disinfectant through the channel using a
syringe that luer-locks onto the scope port. Actively fill the channel and syringe multiple times with the high-level disinfectant until no air bubbles exist in the
scope or the syringe. The scope should remain submerged.
• The exposure time and temperature for disinfecting patient care equipment varies among the FDA-cleared high-level disinfectants. Follow the FDA-cleared label
claim for high-level disinfection unless several well-designed experimental scientific studies, endorsed by professional societies, demonstrate an alternative
exposure is effective for disinfecting semicritical items. Multiple scientific studies and professional organizations support the efficacy of >2% glutaraldehyde for
20 minutes at 20°C.22,25 Perform routine testing (eg, before each use, daily, per manufacturer’s recommendations) of the liquid high-level disinfectant to ensure
at least the minimum effective concentration of the active ingredient.
• Rinse with sterile water: if filtered water or tap water is used, follow with an alcohol rinse (not immersion of the cystoscope in alcohol) to enhance drying (and no
residual water is left for microbial growth)
• Dry the device: dry all channels with medical grade forced air until the air is dry; dry the outside with a lint-free disposable cloth
• Storage: appropriately store the device to ensure the device is not recontaminated
• When using high-level disinfectants, personal protective equipment should be worn as recommended (eg, gloves, gown, faceshield)
• If an AER is used, ensure that the manufacturer’s recommended channel connectors are properly used
Sterilization
• Alternatively, low-temperature sterilization technology (eg, ethylene oxide, hydrogen peroxide plasma) may be an option for heat-sensitive equipment, such as
cystoscopes, but the user must comply with the cystoscope and sterilizer manufacturer’s recommendations
AER, automated endoscope reprocessor; FDA, Food and Drug Administration.
*Users should be familiar with the manufacturer’s recommendations for use and high-level disinfection or sterilization of the specific device used by the facility. Anaphy-
lactic reactions have been reported in patients with bladder cancer who underwent repeated cystoscopies using scopes that were high-level disinfected with ortho-
phthalaldehyde; consequently, ortho-phthalaldehyde is contraindicated in patients with a history of bladder cancer.Adapted from Cambridge University Press.96
pouch or a closed plastic bag. Examples of noncompliant storage
would include unwrapped blades in an anesthesia drawer and an
unwrapped blade on top of or within a code cart. The packaging
not only prevents recontamination but also distinguishes a pro-
cessed from a nonprocessed semicritical item, such as a specula,
laryngoscope blade, or endoscope. The use of a tagging system that
separates processed from nonprocessed items minimizes the use
of semicritical items that have not been reprocessed and prevents
patient exposure to a nonreprocessed semicritical item.7 This could
involve a tag (eg, green tag: patient ready, red tag: requires repro-
cessing) for GI endoscopes or a plastic sheath or plastic-paper peel
pouch (eg, endocavitary probes). Ideally, hospitals and ambulato-
ry care facilities (as appropriate)20 should develop a strategy (eg,
tagging, storage covers for patient-ready devices) that prevents
patient exposure to contaminated devices.
Human papilloma virus
Human papilloma virus is an extremely common sexually ac-
quired infection and is the most important cause of cervical cancer.
A recent article demonstrated that the FDA-cleared high-level dis-
infectants (ie, glutaraldehyde, ortho-phthalaldehyde) tested did not
inactivate the human papilloma virus, a nonenveloped virus.98 These
findings are inconsistent with many articles in the peer-reviewed
literature, which demonstrate that HLD, such as by OPA and glu-
taraldehyde, inactivates nonenveloped viruses, such as human
papilloma virus, polio, adenovirus, norovirus, and so forth.15 Because
HLDs are commonly used to disinfect endocavitary probes (eg,
vaginal probes, rectal probes), there is an urgency to corroborat-
ing these data. In a conversation with CDC staff regarding this issue,
it was determined hospitals should continue to use the FDA-
cleared high-level disinfectants consistent with the manufacturers’
instructions until the data can be corroborated. Data have demon-
strated the activity of a hydrogen peroxide mist device to inactivate
the human papilloma virus.74
Do not reuse single-use devices
The Department of Justice and the FDA have joined forces in pros-
ecuting health care providers that reuse single-use devices. For
example, a physician was criminally prosecuted for reusing needle
guides meant for single use during prostate procedures. These pros-
ecutions are based on conspiracy to commit adulteration and
Medicare fraud. Third-party reprocessing is allowed by the FDAwhen
the reprocessor is considered the device manufacturer, as defined
under 21 CFR Part 820.
CONCLUSIONS
Strict adherence to current guidelines is required for semicritical
items because more outbreaks have been linked to inadequately
cleaned or disinfected semicritical items, such as endoscopes, un-
dergoing HLD than any other reusable medical device.
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